PaulG.CornMD

Oncology • Houston, TX

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,

Join to view full profile

Are you Dr. Corn?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 84 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Dr. Paul Corn, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center and is an Associate Professor at Division of Cancer Medicine.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1996 - 1999
University of ChicagoResidency, Internal Medicine, 1993 - 1996
Georgetown University School of MedicineClass of 1993

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2005 - 2026
OK State Medical License 2020 - 2021
PA State Medical License 2000 - 2004
MD State Medical License 1996 - 2000

Clinical Trials

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer Start of enrollment: 2008 Feb 01
Completed
Phase 1
TKI258 in Castrate Resistant Prostate Cancer Start of enrollment: 2010 Apr 07
Completed
Phase 2
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer Start of enrollment: 2014 Jan 08
Completed
Phase 2
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Start of enrollment: 2014 May 19
Terminated
Phase 2
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

187 citations
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene O. Siefker-Radtke, Matthew T. Campbell
Nature Medicine. 2020-10-12
17 citations
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Bilal A. Siddiqui, Jinesh S. Gheeya, Rohit V. Goswamy, Tharakeswara K. Bathala, Devaki Shilpa Surasi
Journal for Immunotherapy of Cancer. 2021-07-01
1 citations
Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.
Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn
The Journal of Urology. 2024-06-01

Press Mentions

Cancer Death Rates down but Racial Disparities Persist Among Black Men and WomenJanuary 12th, 2023
Expert Sees Checkpoint and PARP Inhibitors Building on mCRPC SuccessMarch 14th, 2017
Study Identifies Possible New Combination Chemotherapy for Patients with Advanced Prostate CancerMay 30th, 2015

Grant Support

Regulation Of The Von Hippel-Lindau ProteinNational Cancer Institute2004–2007
Regulation Of The Von Hippel-Lindau ProteinNational Cancer Institute2003